Tumoral PD-L1 does not impact time to treatment discontinuation in EGFR mutated non-small cell lung cancer patients treated with EGFR tyrosine kinase inhibitor—a Danish cohort study

Julie Gabe Dissing, Maiken Parm Ulhøi, Boe Sandahl Sorensen, Peter Meldgaard